Core Laboratories Inc Financials
This page shows Core Laboratories Inc (CLB) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Core Laboratories now looks like a cash-funded deleveraging business, using stable revenue to steadily lighten leverage.
Between FY2023 and FY2025, debt-to-equity fell from 0.7x to 0.4x even though revenue barely moved, so the balance sheet improved mainly through cash retention and debt paydown rather than scale. The clue is free-cash-flow volatility: it jumped to$44.5M in FY2024 and settled at$25.8M in FY2025, showing that working-capital releases have been an important support for deleveraging.
FY2025's gross margin improved to
Liquidity is working-capital dependent more than cash-rich: year-end cash was
Financial Health Signals
Based on FY2025 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Core Laboratories Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Core Laboratories Inc has an operating margin of 10.7%, meaning the company retains $11 of operating profit per $100 of revenue. This results in a moderate score of 46/100, indicating healthy but not exceptional operating efficiency. This is down from 11.2% the prior year.
Core Laboratories Inc's revenue grew a modest 0.5% year-over-year to $526.5M. This slow but positive growth earns a score of 36/100.
Core Laboratories Inc carries a low D/E ratio of 0.41, meaning only $0.41 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 94/100, indicating a strong balance sheet with room for future borrowing.
Core Laboratories Inc's current ratio of 2.02 indicates adequate short-term liquidity, earning a score of 37/100. The company can meet its near-term obligations, though with limited headroom.
Core Laboratories Inc has a free cash flow margin of 4.9%, earning a moderate score of 39/100. The company generates positive cash flow after capital investments, but with room for improvement.
Core Laboratories Inc's ROE of 11.2% shows moderate profitability relative to equity, earning a score of 39/100. This is down from 12.7% the prior year.
Core Laboratories Inc scores 3.01, well above the 2.99 safe threshold. This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Core Laboratories Inc passes 7 of 9 financial strength tests. 3 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Core Laboratories Inc generates $1.25 in operating cash flow ($37.0M OCF vs $29.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Core Laboratories Inc earns $5.3 in operating income for every $1 of interest expense ($56.5M vs $10.6M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
Core Laboratories Inc generated $526.5M in revenue in fiscal year 2025. This represents an increase of 0.5% from the prior year.
Core Laboratories Inc's EBITDA was $71.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 3.3% from the prior year.
Core Laboratories Inc reported $29.7M in net income in fiscal year 2025. This represents a decrease of 5.5% from the prior year.
Core Laboratories Inc earned $0.63 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 4.5% from the prior year.
Cash & Balance Sheet
Core Laboratories Inc generated $25.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 42.0% from the prior year.
Core Laboratories Inc held $22.7M in cash against $110.3M in long-term debt as of fiscal year 2025.
Core Laboratories Inc paid $0.04 per share in dividends in fiscal year 2025. This represents an increase of 0.0% from the prior year.
Core Laboratories Inc had 46M shares outstanding in fiscal year 2025. This represents a decrease of 1.6% from the prior year.
Margins & Returns
Core Laboratories Inc's gross margin was 20.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.0 percentage points from the prior year.
Core Laboratories Inc's operating margin was 10.7% in fiscal year 2025, reflecting core business profitability. This is down 0.5 percentage points from the prior year.
Core Laboratories Inc's net profit margin was 5.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 0.4 percentage points from the prior year.
Core Laboratories Inc's ROE was 11.2% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 1.6 percentage points from the prior year.
Capital Allocation
Core Laboratories Inc spent $12.4M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 134.2% from the prior year.
Core Laboratories Inc invested $11.2M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 5.7% from the prior year.
CLB Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $121.8M-11.9% | $138.3M+2.8% | $134.5M+3.4% | $130.2M+5.3% | $123.6M-4.4% | $129.2M-3.8% | $134.4M+2.9% | $130.6M |
| Cost of Revenue | $102.1M-6.8% | $109.5M+4.4% | $104.9M+1.2% | $103.7M+4.3% | $99.5M-6.3% | $106.2M-0.6% | $106.8M+3.8% | $102.9M |
| Gross Profit | $19.7M-31.4% | $28.7M-3.0% | $29.6M+12.0% | $26.5M+9.7% | $24.1M+4.7% | $23.0M-16.5% | $27.6M-0.2% | $27.6M |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $14.7M+38.4% | $10.6M-0.5% | $10.7M+2.1% | $10.5M-23.3% | $13.6M+50.3% | $9.1M+5.1% | $8.6M-15.8% | $10.3M |
| Operating Income | $1.9M-88.1% | $15.8M-24.4% | $20.9M+36.9% | $15.3M+246.2% | $4.4M-68.8% | $14.2M-28.4% | $19.8M+23.7% | $16.0M |
| Interest Expense | $2.9M+10.8% | $2.6M-1.5% | $2.6M-2.3% | $2.7M+4.2% | $2.6M-1.0% | $2.6M-15.4% | $3.1M-3.1% | $3.2M |
| Income Tax | -$251K-103.1% | $8.1M+115.6% | $3.8M+96.4% | $1.9M+9.5% | $1.7M-57.2% | $4.1M-13.1% | $4.7M+30.0% | $3.6M |
| Net Income | -$789K-115.9% | $4.9M-65.3% | $14.2M+33.9% | $10.6M+7006.5% | -$154K-102.1% | $7.4M-37.0% | $11.7M+30.0% | $9.0M |
| EPS (Diluted) | $-0.02 | N/A | $0.30+36.4% | $0.22 | $0.00 | N/A | $0.25+31.6% | $0.19 |
CLB Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $587.7M+0.6% | $584.0M-1.2% | $591.4M-1.8% | $602.1M+2.7% | $586.2M+0.2% | $585.1M-2.6% | $600.5M+0.4% | $597.8M |
| Current Assets | $214.4M-0.1% | $214.7M-5.4% | $226.9M-4.5% | $237.7M+3.9% | $228.8M+3.4% | $221.3M-5.9% | $235.2M+0.7% | $233.5M |
| Cash & Equivalents | $22.8M+0.5% | $22.7M-11.4% | $25.6M-17.8% | $31.2M+41.1% | $22.1M+15.4% | $19.2M-10.8% | $21.5M+21.4% | $17.7M |
| Inventory | $57.8M+6.0% | $54.5M-6.4% | $58.2M-2.6% | $59.8M+1.3% | $59.0M-0.6% | $59.4M-9.3% | $65.5M-6.3% | $69.9M |
| Accounts Receivable | $108.3M-4.6% | $113.5M+3.0% | $110.3M-3.2% | $113.9M-2.7% | $117.0M+4.7% | $111.8M-5.0% | $117.6M+1.7% | $115.6M |
| Goodwill | $105.8M0.0% | $105.8M+5.8% | $100.0M0.0% | $100.0M+0.6% | $99.4M0.0% | $99.4M0.0% | $99.4M0.0% | $99.4M |
| Total Liabilities | $318.8M+0.3% | $318.0M-0.6% | $320.0M-6.1% | $340.8M+2.4% | $332.9M-1.7% | $338.6M-3.2% | $349.7M-2.2% | $357.5M |
| Current Liabilities | $104.7M-1.2% | $106.0M+10.7% | $95.7M-8.6% | $104.8M+1.0% | $103.7M+1.3% | $102.4M+7.9% | $94.9M-2.7% | $97.6M |
| Long-Term Debt | $114.5M+3.8% | $110.3M-3.4% | $114.1M-8.4% | $124.6M+0.2% | $124.4M-1.4% | $126.1M-9.8% | $139.9M-5.2% | $147.6M |
| Total Equity | $268.9M+1.1% | $266.0M-2.0% | $271.3M+3.9% | $261.3M+3.1% | $253.4M+2.8% | $246.6M-1.7% | $250.7M+4.4% | $240.3M |
| Retained Earnings | $171.4M-0.7% | $172.7M-0.5% | $173.6M+8.6% | $159.8M+6.8% | $149.7M+3.3% | $144.9M+1.1% | $143.3M+8.5% | $132.1M |
CLB Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $4.0M-50.1% | $7.9M-6.5% | $8.5M-38.9% | $13.9M+109.1% | $6.7M-67.7% | $20.6M+57.4% | $13.1M-23.6% | $17.1M |
| Capital Expenditures | $3.4M+17.1% | $2.9M+46.8% | $2.0M-42.3% | $3.5M+24.7% | $2.8M-14.1% | $3.2M+18.8% | $2.7M-4.8% | $2.9M |
| Free Cash Flow | $517K-89.7% | $5.0M-23.0% | $6.5M-37.8% | $10.4M+169.7% | $3.9M-77.7% | $17.4M+67.6% | $10.4M-27.4% | $14.3M |
| Investing Cash Flow | -$3.4M+9.6% | -$3.8M-256.8% | $2.4M+245.6% | -$1.6M-313.0% | $772K+121.7% | -$3.6M-624.8% | -$491K+28.5% | -$687K |
| Financing Cash Flow | -$457K+93.6% | -$7.1M+56.7% | -$16.5M-414.5% | -$3.2M+28.6% | -$4.5M+76.9% | -$19.4M-119.5% | -$8.8M+35.5% | -$13.7M |
| Dividends Paid | $460K-1.3% | $466K+0.2% | $465K-0.9% | $469K0.0% | $469K0.0% | $469K0.0% | $469K-0.2% | $470K |
| Share Buybacks | $4.0M+50.5% | $2.7M-47.0% | $5.0M+82.9% | $2.7M+35.5% | $2.0M-58.8% | $4.9M+2402.0% | $196K+21.0% | $162K |
CLB Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 16.2%-4.6pp | 20.8%-1.2pp | 22.0%+1.7pp | 20.3%+0.8pp | 19.5%+1.7pp | 17.8%-2.7pp | 20.5%-0.6pp | 21.2% |
| Operating Margin | 1.6%-9.9pp | 11.5%-4.1pp | 15.6%+3.8pp | 11.8%+8.2pp | 3.6%-7.4pp | 11.0%-3.8pp | 14.7%+2.5pp | 12.3% |
| Net Margin | -0.7%-4.2pp | 3.6%-7.0pp | 10.6%+2.4pp | 8.2%+8.3pp | -0.1%-5.8pp | 5.7%-3.0pp | 8.7%+1.8pp | 6.9% |
| Return on Equity | -0.3%-2.1pp | 1.9%-3.4pp | 5.3%+1.2pp | 4.1%+4.1pp | -0.1%-3.1pp | 3.0%-1.7pp | 4.7%+0.9pp | 3.8% |
| Return on Assets | -0.1%-1.0pp | 0.9%-1.6pp | 2.4%+0.6pp | 1.8%+1.8pp | -0.0%-1.3pp | 1.3%-0.7pp | 2.0%+0.4pp | 1.5% |
| Current Ratio | 2.05+0.0 | 2.02-0.3 | 2.37+0.1 | 2.27+0.1 | 2.21+0.0 | 2.16-0.3 | 2.48+0.1 | 2.39 |
| Debt-to-Equity | 0.43+0.0 | 0.410.0 | 0.42-0.1 | 0.48-0.0 | 0.49-0.0 | 0.51-0.0 | 0.56-0.1 | 0.61 |
| FCF Margin | 0.4%-3.2pp | 3.6%-1.2pp | 4.8%-3.2pp | 8.0%+4.9pp | 3.1%-10.3pp | 13.4%+5.7pp | 7.7%-3.2pp | 10.9% |
Similar Companies
Frequently Asked Questions
What is Core Laboratories Inc's annual revenue?
Core Laboratories Inc (CLB) reported $526.5M in total revenue for fiscal year 2025. This represents a 0.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Core Laboratories Inc's revenue growing?
Core Laboratories Inc (CLB) revenue grew by 0.5% year-over-year, from $523.8M to $526.5M in fiscal year 2025.
Is Core Laboratories Inc profitable?
Yes, Core Laboratories Inc (CLB) reported a net income of $29.7M in fiscal year 2025, with a net profit margin of 5.6%.
What is Core Laboratories Inc's EBITDA?
Core Laboratories Inc (CLB) had EBITDA of $71.1M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Core Laboratories Inc have?
As of fiscal year 2025, Core Laboratories Inc (CLB) had $22.7M in cash and equivalents against $110.3M in long-term debt.
What is Core Laboratories Inc's gross margin?
Core Laboratories Inc (CLB) had a gross margin of 20.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Core Laboratories Inc's operating margin?
Core Laboratories Inc (CLB) had an operating margin of 10.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Core Laboratories Inc's net profit margin?
Core Laboratories Inc (CLB) had a net profit margin of 5.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Core Laboratories Inc pay dividends?
Yes, Core Laboratories Inc (CLB) paid $0.04 per share in dividends during fiscal year 2025.
What is Core Laboratories Inc's return on equity (ROE)?
Core Laboratories Inc (CLB) has a return on equity of 11.2% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Core Laboratories Inc's free cash flow?
Core Laboratories Inc (CLB) generated $25.8M in free cash flow during fiscal year 2025. This represents a -42.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Core Laboratories Inc's operating cash flow?
Core Laboratories Inc (CLB) generated $37.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Core Laboratories Inc's total assets?
Core Laboratories Inc (CLB) had $584.0M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Core Laboratories Inc's capital expenditures?
Core Laboratories Inc (CLB) invested $11.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Core Laboratories Inc's current ratio?
Core Laboratories Inc (CLB) had a current ratio of 2.02 as of fiscal year 2025, which is generally considered healthy.
What is Core Laboratories Inc's debt-to-equity ratio?
Core Laboratories Inc (CLB) had a debt-to-equity ratio of 0.41 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Core Laboratories Inc's return on assets (ROA)?
Core Laboratories Inc (CLB) had a return on assets of 5.1% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Core Laboratories Inc's Altman Z-Score?
Core Laboratories Inc (CLB) has an Altman Z-Score of 3.01, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Core Laboratories Inc's Piotroski F-Score?
Core Laboratories Inc (CLB) has a Piotroski F-Score of 7 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Core Laboratories Inc's earnings high quality?
Core Laboratories Inc (CLB) has an earnings quality ratio of 1.25x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Core Laboratories Inc cover its interest payments?
Core Laboratories Inc (CLB) has an interest coverage ratio of 5.3x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Core Laboratories Inc?
Core Laboratories Inc (CLB) scores 48 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.